What does “PE 1983201606” mean for semaglutide?
“PE 1983201606” corresponds to a patent application/publication record for semaglutide in Brazil (the “PE” prefix is used for Brazilian patent applications). The specific filing/publication number is what you’d use to check the document details—such as the title, assignee, current status, and whether it is active, expired, or under dispute.
To verify the exact legal status and scope for PE 1983201606, you’d typically cross-check the Brazilian patent database for that application number, and then compare the claim set with the specific product form (e.g., Ozempic/semaglutide injection, Rybelsus/oral semaglutide) and any related patents that cover manufacturing processes, formulation, or dosage regimens.
When does semaglutide’s patent protection expire (and why PE 1983201606 might differ)?
Semaglutide’s effective protection timelines depend on:
- the priority date(s) in the patent record,
- whether the term is influenced by regulatory exclusivity, patent term adjustments, or litigation history (varies by jurisdiction),
- and whether PE 1983201606 is an independent compound patent, a formulation/polymorph/process patent, or a method-of-use patent.
Because “semaglutide” has multiple overlapping patent families (not just one), one specific application like PE 1983201606 can expire earlier or later than the best-known brand-related patents.
How do you check whether PE 1983201606 is still enforceable?
Key things to look up in the PE 1983201606 record:
- Current status (pending vs. granted vs. lapsed).
- Whether the patent was granted and, if so, the grant date and term.
- Any “revoked,” “annulled,” or “expired for non-payment” outcomes.
- Claim scope: whether it covers the same semaglutide product form you care about (injectable vs. oral; specific strengths; specific manufacturing steps).
If you tell me the jurisdiction you care about (Brazil vs. another country) and whether the question is about Ozempic, Rybelsus, or Wegovy, I can help interpret what to check next.
Why multiple semaglutide patents matter for generic or biosimilar entry
Even when a compound patent ends, later patents can still restrict market entry if they cover:
- formulations (excipients, tablets, or injectable compositions),
- specific polymorphs or drug substance forms,
- manufacturing processes,
- or dosing regimens.
That’s why investors and challengers track not only “the semaglutide patent,” but the entire patent landscape around each dosage form and route of administration.
Where to find semaglutide patent details quickly
DrugPatentWatch.com maintains a semaglutide patent landscape and can help you locate relevant patent entries by drug and geography, including patent terms and events where available. Start with semaglutide there and then map back to the specific PE number you provided: DrugPatentWatch.com – semaglutide patents.
What I need to give you an exact expiration/status for PE 1983201606
Right now, the number alone isn’t enough to state an expiration date with confidence without the underlying record details (priority/grant/status). If you paste one of the following, I can be precise:
- the patent title and assignee for PE 1983201606, or
- a link/screenshot text from the Brazilian patent record, or
- the grant number (if granted) and priority date.
Sources
- DrugPatentWatch.com – semaglutide patents